The share count went down by 98 million shares for a
Top 10 Most Recent News Articles
SAP Execution Can Steady Operations Beyond Spreadsheets
Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...
Continue Reading
BBW Lawsuit Puts Guidance and Walmart Claims Under Lens
A three-month slice of 2026 has landed Build-A-Bear in the sort of mess investors hate most: a securities complaint centered on whether management's upbeat messaging had already outrun the facts. The lawsuit targets purchases of BBW shares from May 28, 2026 through August 26, 2026, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and...
Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial
A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...
Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan
Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...
Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines
Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...
Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too
A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...
Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype
A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...
Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test
Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...
Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape
Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...
Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look
A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...
Continue ReadingTop 5 Most Recently Viewed Articles
Raphael Bostic's Forecast for Interest Rate Cuts in 2024
Fed's Bostic Discusses Future Interest Rate Cuts Atlanta Federal Reserve President Raphael Bostic has recently shared his insights regarding future interest rate adjustments. At a recent event in Atlanta, Bostic indicated that he has projected a further interest rate decrease of 25 basis points this year. This update follows his review of the central bank's recent...
Continue Reading
Boardwalktech Software to Showcase Innovations at Upcoming Event
Boardwalktech Software Demonstrates Commitment to Innovation Boardwalktech Software Corp. (TSXV: BWLK) (OTCQB: BWLKF), recognized as a leader in the Intelligent Information Platform sector, has announced that their CEO and Chairman, Andrew Duncan, is set to present at the highly anticipated Planet MicroCap Showcase. This event, in partnership with MicroCapClub, serves as...
Continue Reading
Michael Saylor Advocates for U.S. Leadership in Cryptocurrency
Michael Saylor's Vision for Digital Assets Michael Saylor, the co-founder of Strategy Inc. and a prominent advocate for Bitcoin, recently held discussions with key figures in the House Financial Services Committee. His conversations focused on strategies to position the United States as a leading authority in the world of Bitcoin and cryptocurrencies. The Digital Assets...
Continue Reading
Gents Doctor Unveils Insights on Testosterone Therapy and Health
Gents Doctor Shares New Insights on Testosterone Therapy Gents Doctor, a well-known male health clinic led by Dr. Majid Sabour, MD, has recently unveiled two important blog posts that explore significant topics related to Testosterone Replacement Therapy (TRT). These posts are designed to inform men who are interested in improving their health through hormone...
Continue Reading
Promising Results from Phase III POLARIS-1 Study of Olverembatinib
Exciting Developments in the Treatment of Ph+ ALL At the recent American Society of Hematology (ASH) meeting, cutting-edge research on Olverembatinib, a promising drug from Ascentage Pharma, highlighted its impressive efficacy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The findings from the Phase III...
Continue Reading